医疗保险药物治疗管理计划的特征注册者具有中枢神经系统活性多药剂
Anna Hung1,2,3, Lauren E Wilson1, Valerie A Smith1,4,5
1Department of Population Health Sciences, Duke University School of Medicine, Durham, NC.
Journal of managed care & specialty pharmacy
|December 24, 2025
概括
超过10%的医疗保险D部分药物治疗管理 (MTM) 登记者有中枢神经系统 (CNS) 活性多药性. 这些人,通常是男性和双重招生,由于伴随性疾病和医疗保健使用率较高,需要定制干预措施.
科学领域:
- 老年人药房 老年人药房
- 医疗保健服务研究 医疗服务研究
- 公共卫生 公共卫生
背景情况:
- 医疗保险D部分药物治疗管理 (MTM) 旨在减少老年人与药物相关的问题.
- 中枢神经系统 (中枢神经系统) 活性多药是一种重大问题,与老年人的认知障碍和跌倒有关.
- 有限的数据存在于中枢神经系统活性多药的流行率和特征在MTM enrollees.
研究的目的:
- 为了确定全国范围内Medicare MTM注册者中中枢神经系统活性多药物的患病率.
- 为了比较患者人口统计,健康状况和MTM服务使用情况,MTM注册者与没有中枢神经系统活性多药.
主要方法:
- 一项横截面的观察性研究利用了2019-2021年的医疗保险5%服务费数据,与2020-2021年的MTM数据联系在一起.
- 分析了患者的特征和MTM服务的使用情况,并比较了具有和没有中枢神经系统活性多药物的入学者.
主要成果:
- 在2021年,38,733名MTM入学者的10.7%,经历了中枢神经系统活性多药.
- 中枢神经系统活性多药组更有可能是男性,双重注册医疗补助,并具有更高的并发症负担和先前的医疗保健利用率.
- 这一群人也使用处方药的比例较高,但在综合药物评估 (CMR) 的参与率较低,与没有中枢神经系统活性多药群体相比.
结论:
- 中枢神经系统活性多药性影响超过10个MTM注册者中的1个,超过一般的医疗保险受益人数.
- 这些入学者具有复杂的临床和社会经济需求,需要专门的MTM干预.
- 增加CMR参与对于减轻与中枢神经系统活性多药性药物相关的风险至关重要.
更多相关视频
相关概念视频
Drug Therapy
229
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
229
Drug Dosing: Geriatric Patients
206
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
206
Therapeutic Drug Monitoring: Overview and Classification
264
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
264
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
503
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
503
Therapeutic Drug Monitoring: Affecting Factors
170
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
170
Parkinson's Disease: Treatment
933
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
933


